Saxenhofer H, Weidmann P
Medizinische Poliklinik der Universität Bern.
Ther Umsch. 1990 Jun;47(6):509-13.
HMG-CoA reductase inhibitors are a new class of drugs, which inhibit de novo cholesterol biosynthesis and significantly reduces the blood cholesterol concentrations. Three separate inhibitors, lovastatin, simvastatin and pravastatin can lower plasma total cholesterol and low-density lipoprotein (LDL) levels in hypercholesterolemic humans by 20 to 30% and 30 to 40%, respectively. The reduction in the levels of circulating atherogenic lipoprotein particles occurs as a result of decreased synthesis and enhanced removal of LDLs by the LDL receptor pathway in hepatocytes. Moreover, the levels of high-density lipoprotein (HDL-)cholesterol, which are inversely related to atherosclerosis, increase with treatment by these drugs. If the short-term safety of these drugs extends to ongoing longterm studies and if cardiovascular morbidity and mortality are improved by their use, these hypolipidemic agents will facilitate the effective treatment of hypercholesterolemia.
HMG-CoA还原酶抑制剂是一类新型药物，可抑制胆固醇的从头生物合成，并显著降低血液胆固醇浓度。三种不同的抑制剂，洛伐他汀、辛伐他汀和普伐他汀，可使高胆固醇血症患者的血浆总胆固醇和低密度脂蛋白（LDL）水平分别降低20%至30%和30%至40%。循环中致动脉粥样硬化脂蛋白颗粒水平的降低是由于肝细胞中LDL受体途径合成减少和LDL清除增强所致。此外，与动脉粥样硬化呈负相关的高密度脂蛋白（HDL）胆固醇水平会随着这些药物的治疗而升高。如果这些药物的短期安全性能延伸至正在进行的长期研究，并且其使用能改善心血管疾病的发病率和死亡率，那么这些降血脂药物将有助于有效治疗高胆固醇血症。
